Download Files:
Imatinib
$66 – $257
Products Details
Product Description
– Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively[1][2][3][4]. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV[5].
Web ID
– HY-15463
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C29H31N7O
Citations
– Acta Pharmacol Sin. 2022 Nov 30.|Arch Pharm (Weinheim). 2022 Oct 10;e2200367.|Bioanalysis. 2018 Jul;10(14):1099-1113.|Biochem Pharmacol. 2023 Jan 30.|Biomolecules. 2022 Jun 11;12(6):819.|Cancer Biol Ther. 2019;20(6):877-885.|Cancer Lett. 2019 Apr 10;447:105-114.|Cancer Med. 2019 Sep;8(11):5352-5366.|Cell Biosci. 2020 Feb 12;10:16.|Cell Chem Biol. 2018 Aug 16;25(8):996-1005.e4.|Cell Death Dis. 2022 Apr 20;13(4):384.|Cell Metab. 2022 Feb 7;34(3):424-440.e7.|Clin Cancer Res. 2020 Aug 15;26(16):4349-4359.|Clin Chem. 2019 Dec;65(12):1522-1531. |Clin Sci. 2021 Jul 20;CS20210571.|Drug Des Devel Ther. 2022 Aug 4;16:2545-2557.|EMBO Mol Med. 2021 Mar 4;e13144.|Eur J Pharmacol. 2021 Feb 10;173944.|Eur J Pharmacol. 2021 Jun 1;174217.|Eur J Pharmacol. 2021 Nov 26;174633.|Gastric Cancer. 2023 May 24.|Inflamm Regen. 2022 Sep 26;42(1):44.|Int J Mol Sci. 2023 Feb 2;24(3):2849.|J Biomed Inform. 2023 May 15;104383.|J Cell Biochem. 2023 Aug 11.|J Med Chem. 2016 Sep 22;59(18):8456-72. |J Med Chem. 2019 Jul 11;62(13):6083-6101.|J Med Chem. 2019 May 23;62(10):5006-5024. |J Med Chem. 2021 Mar 11;64(5):2725-2738.|J Tradit Complement Med. 2023 Nov 22.|Med Sci Monit. 2017 Aug 6;23:3808-3816.|Mol Carcinog. 2023 Sep 22.|Mol Ther. 2022 Nov 15;S1525-0016(22)00662-1.|Nat Biomed Eng. 2018 Aug;2(8):578-588.|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Oncogene. 2022 Feb 9.|Oncotarget. 2016 Jul 19;7(29):45562-45574.|Oncotarget. 2017 Nov 15;8(67):111110-111118. |Patent. US20200276189A1.|Patent. US20220064117A1.|Patent. US20220288064A1.|Patent. US20230158019A1.|Research Square Preprint. 2021 May.|Sci Immunol. 2023 Mar 17;8(81):eade4656.|Sci Signal. 2019 Jul 16;12(590). pii: eaav7259.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Sensor Actuat B-Chem. 2021, 128991.|Signal Transduct Target Ther. 2023 Mar 1;8(1):90.|Stem Cell Reports. 2017 Dec 12;9(6):1948-1960.|Ther Adv Med Oncol. 2019 May 17;11:1758835919849757. |Theranostics. 2021 Jan 1;11(6):2691-2705.|Toxicol Lett. 2022 Jun 6;S0378-4274(22)00117-5.|Toxicol Lett. 2022 May 18;363:11-26.|Viruses. 2021 May 31;13(6):1035.|Anticancer Drugs. 2014 Jul;25(6):673-82.|Biomed Chromatogr. 2019 Dec;33(12):e4674.|BMC Med. 2022 Aug 24;20(1):257|Harvard Medical School LINCS LIBRARY|J Bioenerg Biomembr. 2012 Feb;44(1):155-61.|J Pers Med. 2023, 13(1), 146.|Mol Cell Biochem. 2020 Jan;463(1-2):67-78|Nat Immunol. 2023 Sep;24(9):1443-1457.|Oncotarget. 2018 Apr 24;9(31):22158-22183. |Patent. US20220242943A1.|Pharmaceutics. 2023 Sep 12, 15(9), 2305.|PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. |PLoS One. 2017 Jun 1;12(6):e0178619.|Research Square Preprint. 2023 Nov 20.
References
– [1]Iqbal N, et al. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.|[2]Guida T, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13(11):3363-9.|[3]Okuda K, et al. ARG tyrosine kinase activity is inhibited by STI571.Blood. 2001 Apr 15;97(8):2440-8|[4]Yao JC, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 1;13(1):234-40.|[5]Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96(3):925-32.|[6]Sun XC, et al. Depletion of telomerase RNA inhibits growth of gastrointestinal tumors transplanted in mice. World J Gastroenterol. 2013 Apr 21;19(15):2340-7.|[7]Jeanne M Sisk, et al. Coronavirus S Protein-Induced Fusion Is Blocked Prior to Hemifusion by Abl Kinase Inhibitors. J Gen Virol. 2018 May;99(5):619-630.|[8]Coleman CM, et al, Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016;90(19):8924‐8933. Published 2016 Sep 12.|[9]Yildiz C, et al. Effect of imatinib on growth of experimental endometriosis in rats. Eur J Obstet Gynecol Reprod Biol. 2016 Feb;197:159-63.
CAS Number
– 152459-95-5
Molecular Weight
– 493.60
Compound Purity
– 99.95
SMILES
– CN(CC1)CCN1CC2=CC=C(C(NC3=CC=C(C)C(NC4=NC(C5=CC=CN=C5)=CC=N4)=C3)=O)C=C2
Clinical Information
– Launched
Research Area
– Cancer
Solubility
– DMSO : 12.5 mg/mL (ultrasonic)|H2O : 10 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Autophagy;Bcr-Abl;c-Kit;PDGFR;SARS-CoV
Pathway
– Anti-infection;Autophagy;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
